In The Spotlight
- 12 September 2017 - 14 September 2017
- Malmömassan – Malmö Convention Center Mässgatan 6 215 32, Malmö
- 05 May 2017 - 07 May 2017
- Bologna Fair Centre
- Bologna, Italy
- 15 May 2017 - 18 May 2017
- National Exhibition and Convention Center
- Shanghai, China
- 28 June 2017 - 30 June 2017
- Tokyo Big Sight, Tokyo
- 28 June 2017 - 30 June 2017
- Tokyo Big Sight, Tokyo
InDex Pharmaceuticals Holding AB announced that the US FDA has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.
Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden.
Epidemiologists conducting national precision medicine initiatives focused on gathering clinical research data on genetic variation among East and South Asian populations now have access to Thermo Fisher Scientific's Applied Biosystems Axiom Asia Precision Medicine Research Array.
BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, announced completion of last patient treatment in its extended Phase I/II clinical study of BST-236 (Astarabine) in acute leukemia patients.
Biohaven Pharmaceutical Holding Company Ltd.
Kite Pharma, Inc , a leading cell therapy company announced that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL) are now being treated in its Phase 2 ZUMA-5 trial with its lead investigational candidate, axicabtagene ciloleucel (axi-cel).
Acasti Pharma Inc announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma.
Sartorius Stedim Biotech (SSB), a leading international supplier to the biopharmaceutical industry announced an agreement with Nova Biomedical (Nova), a well-known US manufacturer of cell culture analyzers, to integrate their BioProfile® FLEX2 into the ambr® multi-parallel bioreactor systems for automated, at-line cell culture analytics.
Contract development and manufacturing organisation (CDMO) Saneca Pharma has been granted a multiple dosage form approval for the manufacture and supply of solids, semi-solids and liquid finish dose products to Russia.
Manufacturers require high code accuracy and legibility from their Thermal Transfer Overprinters to improve production line efficiency and reduce overall costs.
With the recent increase in health consciousness globally, the concept of "farm to fork" has swept the world. As a result of this, the search for methods to reduce food loss and waste in the supply chain from the farm to the dining table, has becomea critical problem to solve; from the perspectives of both economics and environmental protection.
A Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with the installation of new automatic capsule filling capabilities at its EU-GMP approved plant in Pamplona, Spain.
Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers. If this data were liberated to the masses, we would venture into a world of endless possibilities where the search for new cures and treatments could be accelerated.
The Mundipharma network of independent associated companies announced that it has acquired from CellAct the worldwide development, commercialization and manufacturing rights to CAP7.1.
Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.
TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the second quarter of 2017.
A method of testing drugs thatprompt the immune system to attack and destroy cancer cells has been developed which can speed up drug discovering andreducethe unnecessary use of mice in drug screening programmes.
Orphan genetic diseases have become an increasingly popular area for drug development through a variety of novel mechanistictherapeutic approaches.
Automation in its broadest sense has expanded from its original industrial manufacturing base to laboratories and businesses.
KemPharm, Inc. , a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced preliminary results of KP415.109.
Selvita S.A. and The Leukemia & Lymphoma Society (LLS) announced a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia (AML).
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas aeruginosa.